Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/9/2024 | $90.00 | Buy → Neutral | Sidoti |
6/21/2024 | $65.00 → $93.00 | Neutral → Buy | DA Davidson |
11/17/2022 | $71.00 | Buy | Canaccord Genuity |
5/10/2022 | $65.00 → $70.00 | Hold → Buy | Jefferies |
5/9/2022 | $63.00 | Perform → Outperform | Oppenheimer |
3/11/2022 | $156.00 → $142.00 | Outperform | BMO Capital |
11/15/2021 | $61.00 → $63.00 | Neutral | DA Davidson |
11/5/2021 | $123.00 → $126.00 | Sector Perform | RBC Capital |
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
4/A - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)
Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00
DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously
Canaccord Genuity initiated coverage of Prestige Consumer with a rating of Buy and set a new price target of $71.00
DEF 14A - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
10-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)
TARRYTOWN, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- Medtech Products Inc., a Prestige Consumer Healthcare Inc. company ("Medtech" or "Company"), is voluntarily recalling five lots of Little Remedies® Honey Cough Syrup (the "Product") due to the presence of Bacillus cereus and loss of shelf-stability. Bacillus cereus (B. cereus) can cause two types of food-borne illnesses. One type is characterized by nausea, vomiting, and stomach cramps that can start 1 to 6 hours after eating or drinking contaminated food. The second type can cause stomach cramps and diarrhea that can start 8 to 16 hours after eating or drinking contaminated food. Diarrhea may be a small volume or profuse and watery. Altho
TARRYTOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference virtually on Wednesday, June 11, 2025 at 10:30 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors" section and the "Events and Presentations" tab, or by using the following link: https://ir.prestigebrands.com/events-presentations/events For those unable to participate during the live webcast, a replay option will be available on the Company's website following the event. About Prestige Consumer Heal
Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, wh
Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic
Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, wh
Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, which
TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10
SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)
SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)